Gadolinium News and Research

RSS

Design of gold nanoparticles for magnetic resonance imaging

Molecular complexes containing the element gadolinium are proven agents for increasing the diagnostic utility of magnetic resonance imaging (MRI), but their use in detecting small tumors is limited by the relatively weak signal these agents produce.

29 Jan 2007

Link between MRI contrast agent and nephrogenic systemic fibrosis

New research has shown a possible association between a popular magnetic resonance imaging (MRI) contrast agent and the incidence of a rare disease called nephrogenic systemic fibrosis (NSF) in patients with kidney disease, according to an editorial appearing in the March issue of Radiology.

28 Jan 2007

Optical and magnetic resonance imaging of cell death and platelet activation using annexin A5-functionalized quantum dots

By combining a quantum dot with a novel carrier of the magnetic resonance imaging (MRI) agent gadolinium, a team of investigators at the University of Maastricht, in The Netherlands, has developed a nanoparticle that can spot apoptosis, or programmed cell death, using both MRI and fluorescence imaging.

8 Jan 2007

FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents

Alloys of iron and cobalt generate powerful magnetic signals that could be useful in nanoparticles designed to detect tumors using magnetic resonance imaging (MRI).

18 Dec 2006

Functionalization of individual ultra-short single-walled carbon nanotubes

While most research aimed at developing carbon nanotubes as tumor-targeting drug and imaging agent delivery vehicles has focused on full-length nanotubes, Lon Wilson, Ph.D., and his colleagues at Rice University have been working with ultra-short nanotubes that cells appear to take up more efficiently than their longer counterparts.

23 Oct 2006

Nanoscale metal-organic frameworks as potential multimodal contrast enhancing agents

By combining the properties of inorganic and organic molecules in one material, researchers at the Carolina Center of Cancer Nanotechnology Excellence (CCNE) have developed a new class of nanomaterials that can be used to create multifunctional nanoparticles.

10 Jul 2006

MRI clues identify stroke victims at risk of skull hemorrhaging

The appearance of parenchymal enhancement of stroke lesions and the hyperintense MCA sign on MRI may help identify stroke patients at risk of hemorrhaging in the skull, says a new study by researchers at Shantou University Medical College in China and the University of Toronto in Canada.

3 May 2006

Multisequential MRI approach improves heart inflammation diagnosis

A multisequential approach to cardiovascular magnetic resonance scans that highlight different aspects of heart structure and function may offer a better and safer way to identify potentially deadly inflammation of the heart muscle, according to a new study (PDF) in the June 7, 2005, issue of the Journal of the American College of Cardiology.

9 Jun 2005

Researchers determine mechanism of action of chemotherapy drug motexafin gadolinium

The chemotherapy drug motexafin gadolinium (brand name: Xcytrin, manufactured by Pharmacyclics, Inc.) works to thwart cancer cells by disrupting key enzymes involved in cellular metabolism, according to a team of researchers led by Joseph Hacia, Ph.D., assistant professor of biochemistry and molecular biology at the Keck School of Medicine of the University of Southern California.

1 May 2005

MRI better than current standard of practice in assessing neoadjuvant chemotherapy in breast cancer patients

More breast cancer patients with large palpable tumors are now undergoing chemotherapy before surgery in an effort to reduce the size of their tumor, and MRI is the best way to predict if the chemotherapy is working, preliminary results of a study show. If the chemotherapy is successful, then the woman may be able to undergo breast-conservation surgery rather than a mastectomy.

3 Mar 2005

Sex hormones modulate brain damage in multiple sclerosis

Abnormalities in sex hormone levels may contribute to the damage to brain tissue typical of multiple sclerosis, indicates research in the Journal of Neurology Neurosurgery and Psychiatry.

16 Jan 2005

FDA approval of Tysabri, for the treatment of multiple sclerosis

Biogen and Elan Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved Tysabri (natalizumab), as treatment for relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses.

24 Nov 2004

MRI is becoming more recognized as useful in the etiological investigation of sudden deafness

For the patient, sudden deafness can be terrifying. For the specialist, this disorder can be most challenging for the cause of sudden deafness cannot be readily determined by use of the most advanced diagnostic tests.

17 Sep 2004

New MRI Liver Contrast Agent Primovist(TM) Approved in Sweden

Schering AG Group, Germany has announced that the Swedish health authority MPA has granted marketing approval for its innovative liver imaging product Primovist(TM) (gadoxetic acid disodium). Primovist(TM) is designed for the detection and characterization of liver lesions by magnetic resonance imaging (MRI) including liver tumors, metastases as well as other malignant and benign lesions.

5 Apr 2004